Bart Cobert gives his pharmacovigilance point of view on a recent paper on FDA approval timelines and drug safety issues.
Bart Cobert on the importance of publishing clinical trials data and implications on pharmacovigilance.
This is an interesting article looking at what PV will be in the year 2030.
Bart Cobert highlights the most important changes in the recently revised FDA draft guidance on PMRs.
Bart Cobert explores several important points to take from the still ongoing signal and safety issue with Renitidine recall.
Bart Cobert covers several issues involved in setting up the proposed “Safe Importation Plan” which aims to allow US consumers to get safe and cheaper drugs.
An overview covering a number of things to avoid doing when it comes to drug safety.
Bart Cobert explores the potential reasons for the differing regulatory actions from the different agencies.
Dr. Adele Mueller explores the strong patient safety and advocacy responsibility of nurses who work in the pharmaceutical industry.